Gsrsnk Naidu

Gsrsnk Naidu

Auto-generated profile, based on publicly available information

Gsrsnk Naidu

Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research , Chandigarh

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
APArun Prabhahar
Arun Prabhahar
GNG. S. R. S. N. K. Naidu
G. S. R. S. N. K. Naidu
PCPrabhat Chauhan
Prabhat Chauhan
ASAravind Sekar
Aravind Sekar
ASAman Sharma
Aman Sharma
RRRaja Ramachandran
Raja Ramachandran


1 July 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
SSShefali Khanna Sharma
Shefali Khanna Sharma
GNGsrsnk Naidu
Gsrsnk Naidu
The role of danger-associated molecular patterns (DAMPs) in trauma and infections

24 July 2017 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SSShefali Khanna Sharma
Shefali Khanna Sharma
VKVikas Kadiyala
Vikas Kadiyala
GNGsrsnk Naidu
Gsrsnk Naidu
VDVarun Dhir
Varun Dhir

24 June 2019 in Rheumatology
Verified
Journal Article
Closed access
ASAman Sharma
Aman Sharma
RKRajender Kumar
Rajender Kumar
AMAdarsh Mb
Adarsh Mb
GNG S R S N K Naidu
G S R S N K Naidu
VSVikas Sharma
Vikas Sharma
BMBhagwant Rai Mittal
Bhagwant Rai Mittal
Objective: To evaluate 18F-fluorodeoxyglucose (FDG) PET/CT in the assessment of disease activity, extent of the disease and response to therapy in relapsing polychondritis.Methods: Twenty-five patients (9 men, 16 women) with a mean age of 38.2 years (s.d. 13.7; range 18–62), diagnosed to have relapsing polychondritis according to Damiani and Levine’s modification of McAdam’s criteria, who underwent PET/CT examination were included. Ten patients underwent a second PET/CT examination after therapy or during follow-up. Clinical symptoms and auxiliary examination findings were recorded. PET/CT findings were reviewed and correlated with the clinical symptoms.Results: The major symptoms were aural pain (n = 21), nasal pain (n = 10), stridor (n = 5), cough (n = 9), fever (n = 8) and laryngeal tenderness (n = 8). The initial PET/CT was positive in 23/25 patients. PET/CT revealed involvement of auricular (n = 14), nasal (n = 8), laryngeal (n = 7), tracheobronchial (n = 6) and Eustachian (n = 3) cartilages with a mean maximum standardized uptake value (SUVmax) of 4.1 (s.d. 2.5; range 1.7–12.7). Fair correlation of aural/nasal pain/stridor with FDG avidity of cartilage involvement on PET/CT was noted. The key finding was detection of asymptomatic large airway involvement in seven patients (28%). Re-examination PET in 10 patients revealed complete therapeutic response (n = 5), partial response (n = 1), stable disease (n = 1), progressive disease (n = 1) and disease recurrence (n = 2).Conclusion: FDG PET/CT is a useful tool for the assessment of the disease activity and extent. It identified activity in clinically inaccessible sites that are of clinical significance. It is also useful in assessing treatment response and finding relapse.

7 November 2020 in Rheumatology
Verified
Journal Article
Closed access
PDF file
DMDebashish Mishra
Debashish Mishra
VDVarun Dhir
Varun Dhir
GNG S R S N K Naidu
G S R S N K Naidu
AKAastha Khullar
Aastha Khullar
VKVishal Kumar
Vishal Kumar
SJSanjay K. Jain
Sanjay K. Jain
To evaluate the efficacy and safety of a step-down regimen of oral prednisolone over 24 weeks in patients of axial SpA (axSpA). This proof-of-concept double-blind randomized controlled trial enrolled patients with active axSpA (BASDAI ≥4) having predominantly axial disease (≤1 active joint currently) and inadequate response to NSAIDs. They were randomized to receive either oral prednisolone (n = 32) or placebo (n = 33) at a dose of 60, 40, 30, 20, 15 and 10 mg daily for 1 week each, following which they received 5 mg prednisolone (or placebo) daily for 18 weeks. The primary endpoint was a 50% improvement in the BASDAI (BASDAI50) at week 24. Analysis was intention to treat. A BASDAI50 was achieved by 12 of 32 patients (37.5%) in the prednisolone arm and 3 of 33 patients (9.1%) in the placebo arm at 24 weeks [difference 28.4% (95% CI 7.9, 46.7)]. However, there was no difference in achieving a 20 or 40% improvement in the Assessment of SpondyloArthritis international Society response between the groups. Although there was a significant intergroup difference in adjusted ΔBASDAI and ΔAnkylosing Spondylitis Disease Activity Score with CRP at 24 weeks, there was no difference at 12 weeks. There was also no significant difference in ΔBASFI, ΔBAS-G or ΔBASMI at 12 or 24 weeks. No serious adverse events were noted. There was significant weight gain in the first 12 weeks in the prednisolone group vs placebo [0.9 (s.d. 0.4) kg], but not at 24 weeks. In this small study, oral prednisolone was efficacious in axSpA in achieving the primary outcome, but many crucial secondary outcomes such as functional improvement were not met. Its impact on bone loss was not studied. Trial registration: CTRI/2018/01/011342.